Merck: Antidiabetics Market 2018 – 2024 by Segmentation: Based on Product &Application

Germany antidiabetics industry accounted for largest revenue size of USD 4,461.7 million of Europe antidiabetics industry in 2017. According to WHO, in 2016, it was estimated that 22.7% people in Germany are suffering from obesity which is the major risk factor associated with diabetes.

Mortality rate due to diabetes is also increasing at fast pace. Moreover, availability of medicines, technologies and facilities for the disease treatment will stimulate German antidiabetics market growth.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/504

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

 Eli Lilly
 Bayer Corporation
 Novartis
 Johnson & Johnson
 AstraZeneca
 Pfizer
 Bristol-Myers Squibb
 Novo Nordisk
 Merck
 Boehringer Ingelheim
 Oramed Pharmaceuticals
 Takeda Pharmaceutical and Sanofi.

Antidiabetics Market will reach over USD 110 billion by 2024.Growing incidence coupled with increasing risk of diabetes will augment antidiabetics market growth over the coming years. Excess weight significantly escalates risk of type 2 diabetes mellitus (T2DM). Also, the risk of developing diabetes by 25 years of age increases four times in obese children. Thus, rising incidence of diabetes will result into substantial rise in demand for antidiabetics, thereby impelling antidiabetics business growth.

With accelerating growth in number of diabetes cases, prominent players are concentrating their efforts on developing newer and improved antidiabetic drugs. Many leading players including Sanofi, Novo Nordisk and Eli Lilly have a broad pipeline portfolio of antidiabetic drugs that aim to diversify the set of therapeutic alternatives for diabetes patients. Thus, growing R&D activities should positively impact antidiabetics industry growth in forthcoming timeframe.

Insulin product segment is estimated to witness 12.3% CAGR during the forecast period. High revenue share is attributable to widening use of insulin therapy for the treatment of type 2 diabetes. Besides, insulin is available in several forms depending upon its rate of action. In addition, insulin therapy decreases microvascular complications that should boost adoption rate of insulin in the upcoming years.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/504

Geriatric patient population segment accounted for nearly 42.2% market share in 2017 and is estimated to follow similar trend during the forecast timeline. T2DM is an emerging problem in elderly population. As per American Diabetes Association, about 25% of Americans aged above 60 years of age suffer from diabetes. The risk in treating diabetes through changes in dietary habits is further elevated due to impaired physical functioning. Such factors coupled with rising awareness to educate older population about reducing risk of diabetes will act as high impacting factor for geriatric segment growth.

Oral route of administration segment accounted for 72.6% market share in 2017 and will grow at a significant pace during the forecast timeframe due to effectivity and efficacy of treatment coupled with convenience. A study conducted by International Journal of Pharmaceutical Research indicated that oral antidiabetics are most frequently prescribed hypoglycemics. Above factors will highly contribute to segmental growth in projected period.

Browse Report Summery @ https://www.gminsights.com/industry-analysis/antidiabetics-market

India antidiabetics market is estimated to progress at 14.3% CAGR during the forecast timeframe. Growing adoption of binge eating habits as well as accelerating elderly population will considerably contribute to increase in Indian antidiabetics market. Additionally, firms are undertaking organic growth initiatives to expand in Indian market. For instance, Lupin and Boehringer Ingelheim collaborated for co-marketing its oral antidiabetics across India, that should offer lucrative market growth potential in forthcoming years.

Some of the major market players involved in global antidiabetics market are: Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Companies are focusing on partnerships and novel product launch to expand their market presence and enhance customer portfolio.

About Global Market Insights:

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: www.gminsights.com

This release was published on openPR.